Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

With a market cap of $138.2 billion, Pfizer Inc. (PFE) is a leading global biopharmaceutical company headquartered in New ...

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

Pfizer (NYSE: PFE) was on top of the world when it came to earnings and stock price performance. This was in early pandemic times, as the company's coronavirus treatment and vaccine generated enormous ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

The past three years have been challenging for Pfizer (NYSE: PFE). Although Pfizer has made some efforts to turn things around, they have been insufficient. Pfizer's poor performance since 2022 is ...

Pfizer's decision to license SSGJ-707 doesn't make its stock a buy in and of itself. However, the drug candidate is another valuable asset that will be part of the company's plan to improve its ...

This stock's P/CF looks attractive against its industry's average P/CF of 23.11. Over the past 52 weeks, PFE's P/CF has been as high as 43.59 and as low as 8.34, with a median of 13.13.

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...